Inhibition by pirenzepine of nocturnal gastric acid secretion in duodenal ulcer patients.
Ten patients with endoscopically proven duodenal ulcers participated in a double-blind, placebo-controlled, cross-over trial to investigate the effect of pirenzepine on nocturnal gastric acid secretion. Pirenzepine, 50 mg orally at bedtime, inhibited acid secretion all night long: the overall volume secreted and acid output (midnight to 7 a.m.) were significantly less than after placebo. The decrease in acid output per hour was significant at 1,2,3,6, and 7 a.m. It was concluded that controlled clinical trials of maintenance therapy for prevention of relapse of healed duodenal ulcers should be carried out with pirenzepine taken at bedtime.
D000328:Adult; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002940:Circadian Rhythm / Q000187:drug effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010890:Pirenzepine
D001570:Benzodiazepinones; D010879:Piperazines; D010890:Pirenzepine